Article Text
Abstract
Background Takayasu Arteritis is a rare large-vessel vasculitis variant that affects the aorta and its main branches and the pulmonary arteries. Antiphospholipid syndrome is characterized by obstetric and thrombotic complications in the presence of antiphospholipid antibodies, which consist of anticardiolipin antibody, lupus anticoagulant and anti -β2 glycoprotein I. The association of antiphospholipid antibodies and Takayasu arteritis is very rare and few cases decumented it, while others argued aganist such association.
Objectives This study was planned to find out the prevelance of immunoglobulinIgM/G anti-cardiolipinantibodies, anti beta 2 glycoprotein- 1antibodies and lupus anticogulant and evaluate the relationship between these antibodies and disease severity/complications in Takayasu arteritis patients.
Methods 53 patients with Takayasu arteritis patients were enrolled in this study. We obtained blood samples to detectIgM/G anti-cardiolipin antibodies, anti beta 2 glycoprotein 1 antibodies and lupus anticogulant (LA) levels from all patients during their routine control. ImmunoglobulinIgM/G anti-cardiolipin antibody, anti beta 2 glycoprotein 1 antibodies were measured by using a standardized enzyme-linked immunosorbent assay (ELISA) and lupus anticogulant was measured using the diluteRussell's viper venom time (dRVVT).
Results No patients was positive forIgM/G anti-cardiolipin antibody. Seven were positive immunoglobulin IgM anti beta 2 glycoprotein 1 antibodies, three were positive immunoglobulin IgG anti beta 2 glycoprotein 1 antibodies, one waspositive LA. All of the antibody titters were low. TA patients who had antibody positivity had longer disease duration (p<0.05). Antibody and LA positive patients had superior mesenteric artery and celiac artery involvement more frequently then the antibody negative patients (p<0.05).
Conclusions In this study that there were no association between the antibodies positivity and vascular involvement or disease complications and severity in TA patients. In conclusion we can not suggest the routine evaluation of antiphospholipid antibodies or lupus anticoagulant test during the follow-upTakayasu arteritis patients. These antibodies may only be measured in the presence of clinical suspicion.
Disclosure of Interest None declared